Participated · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.

Led · Equity · Mar 2024

RDS is a medtech company focused on remote patient monitoring. Its flagship product, MultiSense, is a patented telemonitoring system that the company develops, manufactures and markets. The company collaborates with international research initiatives such as DARE and 5G-OR and has been incubated at SEMIA/Quest for Health while being accelerated by PariSanté Campus. Emphasizing an eco-conscious approach, RDS aims to set new standards for telemonitoring across Europe. With its latest funding, the firm plans to expand commercialization in France, Germany and the broader European market and to conduct additional clinical trials to support reimbursement applications. The team is simultaneously preparing for FDA registration with the goal of entering the U.S. market in 2028. Elie Lobel leads the company as CEO, and no revenue or user metrics have been disclosed.

Led · Equity · Dec 2023

Singulier, founded in 2017 by Mathieu Ferel and Rémi Pesseguier, offers a "Taskforces As a Service" model that deploys expert teams to support private equity funds and their portfolio companies on strategy, tech, data and AI. It accompanies investors from due diligence through implementation and is increasingly engaged on "exit readiness" assignments for companies preparing to exit within eighteen months. While remaining a people-centric consultancy, Singulier is developing technology products including Holis, a data-analytics platform for investment decision-making, and Graphite, a data infrastructure and analytics team. The firm has been profitable since inception, reported €14 million revenue in 2022, employs 80 people, and has averaged 36% annual growth. The founders plan to use new capital to accelerate hiring, bolster technology, pursue M&A in targeted areas such as product, and expand international activities in the UK and Germany, including recruiting a partner in Germany.

Participated · Series B · Jun 2023

Gleamer is a French med-tech company that builds artificial-intelligence tools to augment radiologists’ workflows. Its flagship platform, Gleamer Copilot, uses computer vision models to detect and quantify abnormalities on imaging studies. The company’s next product line, “OncoView,” will apply the same AI technology to oncology CT scans, initially targeting lung and bone metastases and later expanding to broader cancer imaging needs. Gleamer plans to invest €18 million over the next five years to develop a full suite of applications for lesion detection, measurement, and treatment-response monitoring. The project is being executed in partnership with leading French healthcare institutions and industrial collaborators, and is supported by a dedicated R&D team specializing in AI, data science, and clinical research. A €4.5 million government co-funding award under France’s “Digital Health” initiative will partially finance the effort, underscoring national recognition of the company’s technology and market leadership. Although operating metrics such as revenue or user count were not disclosed, management positions the company as a global leader in AI for medical imaging.

Led · Equity · Jun 2023

BrainTale develops and commercializes BrainTale-care, a clinically validated digital biomarker platform delivered as SaaS that measures white matter using diffusion MRI. The platform identifies white matter microstructure alterations, provides individualized prediction scores, and supports diagnosis, monitoring and prediction for neurological diseases including Alzheimer’s, Parkinson’s, ALS, demyelinating diseases and traumatic brain injury. BrainTale positions its biomarkers to aid physicians and drug developers by improving clinical trial discrimination between active and placebo arms and enabling companion‑biomarker approaches. The company says it will accelerate development and commercial expansion in Europe and the United States following the recent financing. BrainTale was founded in 2018, is supported by LallianSe, employs about a dozen people, and already counts hospitals (Paris Region Greater Hospitals, Hôpitaux Universitaires de Strasbourg), biotech Minoryx and partners including Massachusetts General Hospital among early customers and collaborators. The firm reports its products are clinically validated, ISO 13485:2016 certified and available on the European market under the Medical Device Regulation. BrainTale develops clinically validated digital medical devices and SaaS solutions for neurology and intensive care, focused on quantifying brain lesions and predicting patient outcomes. Its first CE‑marked product, brainQuant, is a SaaS solution that provides brain lesion quantification from diffusion MRI and was launched earlier in 2020. The company is preparing BrainScore‑coma, a SaaS solution that combines brainQuant with AI algorithms to predict coma emergence; it is expected to receive CE marking by mid‑2021. BrainTale’s products are built on more than 15 years of clinical development and prospective trials involving more than 500 patients led by AP‑HP. The company is ISO 13485:2016 certified and intends to use the financing to implement its development and commercialization strategy, accelerate growth, and attract talent. Founded in July 2018, BrainTale positions its solutions as standardized, quality‑checked measures answering unmet medical questions in brain‑injury care.